Stock Research: Alkem Laboratories

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Alkem Laboratories

BSE:539523 INE540L01014
49
  • Value
    50
  • Growth
    43
  • Safety
    Safety
    41
  • Combined
    29
  • Sentiment
    72
  • 360° View
    360° View
    49
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Alkem Laboratories Ltd. is an India-based pharmaceutical company focused on developing, manufacturing, and selling pharmaceutical products. The company operates in pharmaceuticals, producing branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, with offerings in various medical fields including anti-infectives, cardiology, oncology, and more. It markets products in India and over 40 international markets, with the United States as a key focus. In the last fiscal year, the company had a market cap of $6958 millions, profits of $960 millions, and revenue of $1517 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Alkem Laboratories are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Alkem Laboratories. The consolidated Sentiment Rank has a good rank of 72, which means that professional investors are more optimistic about the stock than for 72% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 50 or better than 50% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 41, meaning that the share price of Alkem Laboratories is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 43. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 16-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 61 51 71
Growth
43 25 97 37
Safety
Safety
50 46 42 57
Sentiment
72 27 80 26
360° View
360° View
49 22 88 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
31 15 25 62
Opinions Change
55 31 50 13
Pro Holdings
n/a 42 83 20
Market Pulse
75 54 83 67
Sentiment
72 27 80 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 61 51 71
Growth
43 25 97 37
Safety Safety
50 46 42 57
Combined
29 28 85 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
44 58 38 64
Price vs. Earnings (P/E)
43 48 50 59
Price vs. Book (P/B)
38 45 44 54
Dividend Yield
53 56 47 62
Value
41 61 51 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
54 48 44 39
Profit Growth
54 47 86 34
Capital Growth
13 16 79 73
Stock Returns
65 35 91 47
Growth
43 25 97 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
53 44 48 44
Refinancing
60 60 62 64
Liquidity
50 47 37 57
Safety Safety
50 46 42 57

Similar Stocks

Discover high‑ranked alternatives to Alkem Laboratories and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.